
3RD WORLD CONGRESS on Controversies, Debates & Consensus in **Bone, Muscle & Joint Diseases**



Committees

Co-Chairs

Rick Adachi, Canada Boulos Haraoui, Canada Santiago Palacios, Spain Jean-Pierre Pelletier, Canada Johanne Martel-Pelletier, Canada

Scientific Committee

Cyrus Cooper, UK John Kanis, Belgium Jean-Yves Reginster, Belgium Rene Rizzoli, Switzerland

Invitation

We are proud to announce the 3rd World Congress on Controversies, Debates and Consensus in Bone, Muscle and Joint Diseases (BMJD) held under the auspices of the IOF and ESCEO, which will take place on April 23-26, 2015 in Montreal, Canada.

Over the years, the fields of bone, muscle and joint diseases have undergone enormous expansion in clinical and basic data, as well as that of field-related technology. With the problem of bone, muscle and joint diseases reaching epidemiological dimensions, treatment possibilities have digressed diversely. This development has created a need for debates and discussions on the numerous controversial issues to attain clinical conclusions.

The 3rd edition of BMJD aims to continue facilitating effective debates on unresolved clinical and therapeutic dilemmas, supported by evidence-based medicine and expert opinions resulting in agreement on timely issues. The program provides an effective forum for discussing and debating such unresolved controversies, by allowing ample time for speaker-audience discussions with world authorities in the fields of Osteoporosis, Osteoarthritis, Rheumatoid Arthritis, Pain, Muscles and Joint Diseases.

We are proud to announce that the 3rd BMJD Congress will be held under the auspices of the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), making an even greater impact on the scientific community.

We look forward to your participation and contribution to the 3rd World Congress on Controversies, Debates and Consensus in Bone, Muscle and Joint Diseases (BMJD), and to welcoming you to the delightful city of Montreal.

Key Dates

Call for abstracts Deadline for receipt of abstracts

Tuesday, January 20, 2015

Registration Deadline for early registration Monday, February 2, 2015

CongressMed

Powered by MCI Group

Program Description

OSTEOARTHRITIS

Debates

- Are SYSADOA effective in the treatment of osteoarthritis?
- Will new imaging technologies be more useful for the diagnostic and management of osteoarthritis in daily practice?
- Are exercise and weight loss helpful in reducing disease symptoms and progression?
- Is subchondral bone responsible for the development and progression of osteoarthritis?

Round tables

- Is intraarticular therapy effective for the treatment of OA symptoms?
- Osteoarthritis: A risk factor for cardiovascular disease?
- Is phenotyping of osteoarthritic patients possible and useful?
- Which patients should we treat and how?

Lectures

- · Is osteoarthritis a genetic disease?
- Association between adipokines, inflammation, muscle mass and osteoarthritis structural changes
- Does inflammation play a role in the progression of structural damage in hand osteoarthritis?
- The relevance of an algorithm for the treatment of osteoarthritis
- DMOAD trials: What have we learned from the last decade of experience?
- The usefulness of echography in daily practice with OA patients

OSTEOPOROSIS

Debates

- Drug holiday vs continuous treatment
- Calcium: Is there an upper limit?
 - Treat to target or target to treat?

Round tables

- Secondary prevention
- Fall prevention
- GIOP

Lectures

- Odanacatib
- Atypical femoral fractures
- Lessons from CaMos study

RHEUMATOID ARTHRITIS

- Monotherapy biologics vs. combination therapy?
- · How best to assess disease activity/remission in daily clinical practice?
- Is there still a place for oral corticosteroids in RA?
- Which target to use in a T2T strategy?

Round tables

- Which biologic to use first? Anti TNF or other MOA?
- How to interpret registry safety data?
- Is there still a place for regular X-ray assessment of structural damage in RA
- When is triple therapy indicated in the management of RA?

Lectures

- Epigenetics and RA
- The microbiome in RA
- How to apply the concept of poor prognostic markers in RA
- Biomarkers in daily practice
- Biologics during pregnancy and lactation
- Management of ILD in RA

Be part of the BMJD experience and join us in Montreal



Klal Building, 5 Druyanov St. | Tel Aviv 6314305 | Israel | Tel. +972-73-7066950 Fax. +972-73-7066959 | bmjd@congressmed.com | www.congressmed.com/bmjd